LIAISON Biotrin Parvovirus B19 IgM Plus, LIAISON Biotrin Control Parvovirus B19 IgM Plus
DiaSorin, Inc. · Decision date May 7, 2026
What did the FDA approve?
FDA records P250039 as an original PMA application. The recorded decision is approval, dated May 7, 2026.
FDA approval order statement
Approval for LIAISON Biotrin Parvovirus B19 IgM Plus and LIAISON Biotrin Control Parvovirus B19 IgM Plus. The LIAISON Biotrin Parvovirus B19 IgM Plus, a chemiluminescent immunoassay (CLIA), is intended for the qualitative detection of IgM antibodies to human parvovirus B19 in human serum, lithium heparin, K2-EDTA and sodium citrated plasma. This test, in conjunction with the LIAISON Biotrin Parvovirus B19 IgG Plus (chemiluminescent immunoassay), may be used for testing women of childbearing age to determine their serological status where there is a suspicion of exposure to human parvovirus B19. The results of these assays may be used to make a serological determination of past, recent, or current infection with parvovirus B19. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum). The test must be performed on the LIAISON XL Analyzer.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Microbiology
- Decision date
- May 7, 2026
Regulatory record facts
- Identifier
- P250039
- Regulatory pathway
- Premarket approval application
- Applicant
- DiaSorin, Inc.
- Product code
- MYM
- Decision code
- APPR
- Decision date
- May 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGM.
- Applicant
- DiaSorin, Inc.
- Product code
- MYM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250039 received
Application receipt date recorded by FDA.
P250039 · FDA decision
APPR
P250039/S001 · Related supplement
LIAISON Biotrin Parvovirus B19 IgM Plus, LIAISON Biotrin Control Parvovirus B19 IgM Plus
Timeline entries are records held by MedtechLedger for P250039. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250039
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | PMA supplement | Jun 24, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
DiaSorin, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1951 Northwestern Ave., Stillwater, MN, 55082
Sources and methodology
- Original FDA record: P250039
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records